ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Study Finds Trial Results Reliable At Three Years

July 29, 2005

Linda Weiss, director of NCI Office of Cancer Centers, to Retire in March 2015

November 26, 2014

DCT Board Approves More Than $25 Million In Contract Recompetitions, Two New Contracts

February 23, 1990

New Treatment Projects Get Go-Ahead; Groups Competition To Be Increased, VA Studies Face Cut

November 4, 1977

ODAC Votes for Marqibo Accelerated Approval

March 30, 2012

Community Oncology Alliance Attack On Republican Leadership Prompts Others To Declare: We Aren’t COA.

September 29, 2006